.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Gleneagles Hospital has partnered with Medtronic India to launch a specialized Renal Denervation Therapy Centre at its Parel facility. This initiative specifically targets patients suffering from resistant hypertension. This condition occurs when blood pressure remains high despite the use of multiple medications. Consequently, the centre provides a structured approach to assessment and expert-led intervention. Doctors aim to reduce the risk of heart, brain, and kidney complications through this advanced technology. Therefore, the facility offers clinical evaluation, patient counseling, and medication optimization for eligible individuals.
The new centre will be led by a multidisciplinary team including Dr. Rahul Gupta and Dr. Bharat Shah. Renal Denervation Therapy serves as a minimally invasive procedure that targets overactive nerves in the renal arteries. By using radiofrequency energy, the therapy helps lower blood pressure levels significantly. Dr. Rahul Gupta noted that this therapy offers an additional option for carefully selected patients. Since resistant hypertension increases the risk of stroke and heart failure, early intervention remains crucial. Furthermore, the collaborative model ensures that cardiologists and nephrologists work together for personalized care pathways.
The facility focuses on more than just the surgical procedure. For instance, the team will emphasize lifestyle counseling and regular monitoring to ensure sustained control. Dr. Bharat Shah explained that uncontrolled hypertension can damage kidney function over time. Thus, the specialized centre helps identify high-risk patients early. Mandeep Singh Kumar of Medtronic India stated that the partnership aims to strengthen awareness and improve diagnosis. Moreover, the integration of clinical expertise with advanced technology supports better outcomes for complex cases. Patients will receive medication management support to achieve optimal health results.
Q1: What is resistant hypertension?
Resistant hypertension is a condition where a patient\'s blood pressure remains high even after they take three or more different types of antihypertensive medications.
Q2: How does renal denervation help patients?
The procedure uses radiofrequency energy to disrupt overactive nerves near the kidneys, which helps the body lower blood pressure more effectively.
Q3: Who is eligible for this therapy?
Eligible patients include those with uncontrolled blood pressure who have not responded to standard medical therapies and have been evaluated by a multidisciplinary medical team.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Gleneagles Hospital Mumbai and Medtronic India have launched a Renal Denervation Therapy Centre to treat patients with resistant hypertension....
6 months ago
Explore the emerging role of Brixadi, an extended-release buprenorphine injection, for managing stimulant use disorder through kappa opioid receptor antagonism and steady plasma levels.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
